Search Results
ESAs for the management of lower-risk MDS
Management of Lower-risk MDS without Del5q and Refractory to ESAs
The impact of ESAs in lower-risk MDS
Exploring ESA Treatment Outcomes in Lower-Risk MDS: Expert Perspectives
The optimal treatment of lower risk MDS
The promise of luspatercept for the treatment of lower-risk MDS
The current standard of care for patients with lower-risk MDS
Luspatercept for the treatment of patients with lower-risk MDS and ESA failure
Shifting to Higher Standards in MDS
How is lower-risk MDS treated?
Managing adverse events with novel therapies in lower-risk MDS
Panel Discusses Imetelstat for Lower-Risk MDS Treatment
